All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-HIV-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target HIV-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HIV-1 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of HIV-1 infection.
CAR Construction : X5-41BB-CD3ζ Fig.1 Proliferation mediated by novel CAR interactions with HIV-1-infected target cells. Primary CD8+ T lymphocytes transduced with CARs were enriched to>90% purity and labeled with CellTrace Violet and then cocultured with irradiated HIV-1 NL4-3-infected T2 cells. Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : X5-41BB-CD3ζ Fig.2 Specific killing of HIV-1-infected target cells mediated by novel CARs. CAR-transduced primary CD8+ T lymphocytes were cocultured with HIV-1-infected T2 cells in standard 4-h chromium release assays to assess killing mediated by the CARs. Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : X5-41BB-CD3ζ Fig.3 Efficiencies of novel CAR-transduced primary CD8+ T cells against a panel of HIV-1 isolates CAR-transduced primary CD8+ T cells were tested against a panel of 4 subtype B viruses and one subtype C virus (TZA246) to determine the percent efficiency of log suppression Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006. |
CAR Construction : Fig.4 Binding isotherms of X5 to gp120 and gp120–sCD4. Gp120 and gp120-sCD4 complexes were coated directly on 96-well plates and washed, and X5 was added at the indicated concentrations. Bound X5 was detected by ELISA. Moulard, M., Phogat, S. K., Shu, Y., Labrijn, A. F., Xiao, X., Binley, J. M., ... & Dimitrov, D. S. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120–CD4–CCR5 complexes. Proceedings of the National Academy of Sciences, 99(10), 6913-6918. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-HIV-1 (X5) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ223). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION